Loading clinical trials...
Loading clinical trials...
An Open, 3-cohort, Phase II Trial Testing Oral Administration of Lucitanib in Patients With FGFR1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer
Conditions
Interventions
lucitanib
Locations
29
Australia
Peter MacCallum Cancer Centre
East Melbourne, Australia
Westmead Hospital
Westmead, Australia
Institut Jules Bordet
Brussels, Belgium
Cliniques Universitaires St. Luc Oncology - Breast Clinic
Brussels, Belgium
Grand Hôpital de Charleroi Oncologie-Hématologie
Charleroi, Belgium
UZ Leuven Campus Gasthuisberg Dept. of General Medical
Leuven, Belgium
Start Date
December 1, 2013
Primary Completion Date
March 1, 2017
Completion Date
April 4, 2017
Last Updated
July 25, 2024
NCT07040891
NCT07547774
NCT06257264
NCT05491226
NCT06492759
NCT06681064
Lead Sponsor
Institut de Recherches Internationales Servier
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions